EP-1681: Is understanding of the risks and benefits of radiotherapy affected by the consenting healthcare professional?  by Wolfson, P. et al.
3rd ESTRO Forum 2015                                                                                                                                         S921 
 
EP-1681   
Is understanding of the risks and benefits of radiotherapy 
affected by the consenting healthcare professional? 
P. Wolfson1, T. Carter1, J. Kudhail1, T. Reynolds1, R. Moule1 
1Mount Vernon Cancer Centre, Oncology, London, United 
Kingdom  
 
Purpose/Objective: Informed consent for medical treatment 
is one of the fundamental aspects of modern medical 
treatment, the importance of which becomes even greater 
when there are potentially significant side effects to 
treatment as is the case with radiotherapy. The Quality 
Health 2012 Radiotherapy Patient Experience Survey was 
previously commissioned by the National Radiotherapy 
Implementation Group (NRIG). Following results from this, 
radiotherapy centres in the East of England region repeated 
the survey in 2013. Questions addressed issues of consent and 
understanding of treatment. 
Materials and Methods: Patients receiving radiotherapy in 
October 2013 at 7 centres in the East of England were invited 
to complete a postal patient satisfaction survey following 
their treatment. We analysed the responses to determine if 
patient understanding of the risks and benefits of treatment 
was affected by who consented them (doctor versus 
radiographer) using a chi-squared (x2) test. 
Results: 495 patients across 7 radiotherapy units in the East 
of England Cancer Network completed the postal 
questionnaire. Of these, 69% of patients reported that they 
fully understood the risks and benefits of radiotherapy, 30% 
understood this to some extent and 1% did not understand at 
all. 80% of patients were consented by a consultant 
oncologist, 7% by a doctor other than consultant and 12% 
were consented by a radiographer. 1% could not recall who 
took their consent. Data from 360 patients was available for 
analysis of individual patient responses. This showed that 
significantly more patients completely understood the risks of 
treatment when consented by an oncologist compared to a 
radiographer (x2=10.68, df=2, p<0.05). Patients were also 
more satisfied with the answers to their questions at the time 
of consent if done by an oncologist versus a radiographer 
(x2=7.9, df=2, p<0.05). 
Conclusions: These results suggest that there is increased 
understanding of the risks and benefits of radiotherapy when 
consent is taken by a senior oncology doctor compared to a 
radiographer. Patients also report higher levels of 
satisfaction with how their questions are addressed if a 
doctor versus a radiographer takes their consent. Note should 
be made of the inherent responder and reporter bias present 
in any patient survey. Furthermore, when patients report 
their understanding, responses are very difficult to validate. 
It is vital that informed consent should be taken for all 
patients by an experienced member of the multi-disciplinary 
team who feels confident to address any questions patients 
may have. 
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Purpose/Objective: Radiodermitis remains a major issue 
during breast cancer irradiation. 87% of the patients show 
acute radiodermitis in a variable degree, skin folds are the 
main location. It can cause patient discomfort, treatment 
interruptions, local control loose, and a decrease on quality 
of life. Several factors have been related with radiodermitis 
degree, some of them intrinsic (nutritional status, age, 
health status, associated diseases) and extrinsic (radiation 
dose, energy, fractionation, chemo associated). Up to know, 
no clear consensus exist about which is the best local 
moisture, as well as the timing of its use. Despite several 
local treatments have been recommended there are no 
enough studies to support such recommendations. 
Our aim is to analyse the efficacy of 7 lotions to deal with 
radiodermitis and to evaluate the patient satisfaction 
associated with its use. 
Materials and Methods: We performed a randomized study 
with 2 parallel groups in order to evaluate the efficacy of 7 
moisturizing lotions in order to avoid radiodermitis among 
irradiated breast cancer patients. Patients were evaluated 
weekly with The Radiation-Induced Skin Reaction Assessment 
Scale (RISRAS). This scale evaluates subjective patient's 
symptoms and evaluates objective skin signs by health 
professionals. Irradiation characteristics, patient 
characteristics, lotion used, total irradiation dose, cosmetic 
satisfaction, radiodermitis degree were also recorded. 
Results: 69 patients (p.) were included. Phototype skin (I, 2 
p. (2.8%); II, 16 p. (23.1%); III, 50 p. (72.4%)). Previous 
treatments: chemo 27 p. (39.13%); hormone 64 p. 
(tamoxifen, 35 p. (54.68%); aromatase inh, 29 p. (45.31%), 
antibodies, 5 p. (7.24%). Total dose up to 66 Gy, 63 p. (95%), 
7 p. (11%) also were treated with a bolus. 33% of p. need 
care with an anti-inflammatory and healing ointment, 14% of 
p. need Diprogenta. A tendency towards a wet dermatitis 
reduction was seen for lotions num 3 and 5. (p=0,31). No 
correlation between the RIS-RAS scale and cosmetic 
satisfaction was found (p=0.05), but a significant positive 
correlation was seen between cosmetic satisfaction and the 
overall cosmetic score (table 1). 
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